Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,702 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06270667Recruiting
Exercise training for lymphoma survivors
This study tests whether a supervised exercise program can improve heart health in people who finished treatment for Hodgkin or aggressive non-Hodgkin lymphoma 2–5 years ago. The goal is to see if regular exercise helps your heart recover better after chemotherapy or chest radiation.
OsloAges 20–70 - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT06447090RecruitingPhase 2
VMAC plus donor cells for AML relapse after transplant
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07827586Recruiting
Ocrelizumab injection for relapsing-remitting multiple sclerosis
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
LjubljanaAges 18 years+ - NCT07827716RecruitingPhase 2
Testing terfenadine for relapsing multiple sclerosis
This study tests whether terfenadine, an allergy medicine, is safe and helpful for people with relapsing-remitting multiple sclerosis (MS). It may reduce MS activity and improve outcomes.
Wuhan, HubeiAges 18–65 - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75 - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+ - NCT07778316RecruitingPhase 3
Tarlatamab for small cell lung cancer after first chemotherapy
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
Orlando, FloridaAges 18–99 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07781072RecruitingPhase 2
Immunotherapy plus radiation for advanced head and neck cancer
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06585345RecruitingPhase 1/Phase 2
CD7 CAR-T for relapsed or refractory acute leukemia
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
Chengdu, SichuanAges 14–65 - NCT02919644RecruitingPhase 2
Cancer vaccine made from your own cells after bowel cancer surgery
This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.
Meldola, FCAges 19 years+ - NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24 - NCT07741825Recruiting
Mindfulness training to prevent relapse for peer support workers
This study tests a mindfulness-based program to help people who work as peer support specialists in substance use recovery reduce their risk of relapse. It may help you manage cravings and stay healthy in your role.
Austin, TexasAges 18–100 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT05503134RecruitingPhase 1/Phase 2
Donor immune cell treatment for relapsed or stubborn AML
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Columbus, OhioAges 1–24 - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,702 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.